However, the only and first phase III study with the IGF1R-targeting antibody figitumumab in combination with chemotherapy in non-small-cell lung cancer has been halted due to lack of efficacy as well as due to safety concerns such as hyperglycemia, hemorrhaging and hemoptysis, cardiovascular and cardiopulmonary failure [23]. Here, IGF1R is linked to non-small cell lung carcinoma.